Cutler Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Cutler Group’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-413	Closed	-$1K	–	4122
2018 Q4	$1K	Sell	413 -77	-16%	-$15.4K	﹤0.01%	3576
2018 Q3	$21K	Buy	+490	New	+$79.2K	﹤0.01%	2203
2017 Q4	–	Sell	-297	Closed	-$3K	–	5025
2017 Q3	$3K	Sell	297 -1,333	-82%	-$261K	﹤0.01%	4754
2017 Q2	$14K	Sell	1,630 -463	-22%	-$90.8K	﹤0.01%	3785
2017 Q1	$88K	Buy	2,093 +313	+18%	+$76.8K	﹤0.01%	1856
2016 Q4	$20K	Buy	+1,780	New	+$408K	﹤0.01%	3462

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Cutler Group's CRBP Position: Q1 2024 in Review

Cutler Group opened a new position in Corbus Pharmaceuticals (CRBP) in Q1 2024: 800 shares worth $31K. The stake represents 0.01% of the portfolio and ranks #856 among its holdings. This is a return to the name: Cutler Group previously reported a position in CRBP as recently as Q1 2023.

Cutler Group first reported a position in CRBP in Q3 2016 and has held it in 21 quarters since. The position peaked at $107K in Q4 2016. 82 funds tracked by Wall St. Rank hold CRBP as of Q1 2024.

Cutler Group held 800 shares of Corbus Pharmaceuticals worth $31K as of Q1 2024.
Corbus Pharmaceuticals was a new Cutler Group position in Q1 2024.
Corbus Pharmaceuticals made up 0.01% of Cutler Group's portfolio in Q1 2024, its #856 holding.
Cutler Group first reported a position in Corbus Pharmaceuticals in Q3 2016 and has held it in 21 quarters since.
Cutler Group's Corbus Pharmaceuticals position peaked at $107K in Q4 2016.
82 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.